BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31049637)

  • 21. Precision medicine for advanced prostate cancer.
    Mullane SA; Van Allen EM
    Curr Opin Urol; 2016 May; 26(3):231-9. PubMed ID: 26909474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol.
    Clark E; Morton M; Sharma S; Fisher H; Howel D; Walker J; Wood R; Hancock H; Maier R; Marshall J; Bahl A; Crabb S; Jain S; Pedley I; Jones R; Staffurth J; Heer R
    BMJ Open; 2019 Dec; 9(12):e034708. PubMed ID: 31857319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
    Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
    Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Molecular diagnostics and molecular tumor board in uro-oncology : Precision medicine using the example of metastatic castration-resistant prostate cancer].
    Kornienko K; Tahbaz R; Plage H; Schlomm T
    Urologe A; 2022 Mar; 61(3):311-322. PubMed ID: 35157098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
    De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J
    Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
    Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.
    Buonerba C; Di Lorenzo G; Sonpavde G
    Expert Rev Mol Diagn; 2016 Oct; 16(10):1113-1120. PubMed ID: 27665838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic biomarkers to guide poly(ADP-ribose) polymerase inhibitor precision treatment of prostate cancer.
    Varnai R; Sipeky C
    Pharmacogenomics; 2020 Oct; 21(15):1101-1115. PubMed ID: 33021139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.
    Ghiringhelli F; Richard C; Chevrier S; Végran F; Boidot R
    World J Gastroenterol; 2016 Dec; 22(48):10680-10686. PubMed ID: 28082821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent Advances in DNA Repair Pathway and Its Application in Personalized Care of Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    Xu C; Mao S; Jiang H
    Methods Mol Biol; 2020; 2204():75-89. PubMed ID: 32710316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ; Milowsky MI; Whang YE
    Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Study on the prediction of AR-V7 and CTC circulation in patients with metastatic, castration-resistant prostate cancer (mCRPC) : Correlation between common clinical outcome parameters (rPFS, OS), CTC changes, and AR-V7 status (androgen receptor splice variant 7) in patients with mCRPC on first-line therapy with abiraterone acetate (STAR-V7)-study AP 96/17 of the AUO].
    Rexer H; Hammerer P; Schostak M; König F
    Urologe A; 2017 Dec; 56(12):1615-1617. PubMed ID: 29071394
    [No Abstract]   [Full Text] [Related]  

  • 34. The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells.
    Morra F; Merolla F; Napolitano V; Ilardi G; Miro C; Paladino S; Staibano S; Cerrato A; Celetti A
    Oncotarget; 2017 May; 8(19):31815-31829. PubMed ID: 28415632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Towards precision oncology in advanced prostate cancer.
    Ku SY; Gleave ME; Beltran H
    Nat Rev Urol; 2019 Nov; 16(11):645-654. PubMed ID: 31591549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.
    Athie A; Arce-Gallego S; Gonzalez M; Morales-Barrera R; Suarez C; Casals Galobart T; Hernandez Viedma G; Carles J; Mateo J
    Curr Oncol Rep; 2019 Mar; 21(5):42. PubMed ID: 30919167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular landscape of prostate cancer: implications for current clinical trials.
    Khemlina G; Ikeda S; Kurzrock R
    Cancer Treat Rev; 2015 Nov; 41(9):761-6. PubMed ID: 26210103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
    Coutinho I; Day TK; Tilley WD; Selth LA
    Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.